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With the adoption in the EU of the regulatory 
document of the European Medicines Agency (European 
Medicines Agency) EMA / INS / GMP / 79766/2011 
“Quality Risk Management (ICH Q9)”separate guidance 
was issued in Ukraine in 2011 - Instruction ST-N MOH 42-
4.2: 2011 “Medicines. Quality Risk Management (ICH 
Q9)”. 
Pharmaceutical industry and regulatory bodies 
professionals can assess and manage risk using recognized 
risk management tools and / or internal techniques (e.g., 
standard working methods). The most commonly used risk 
management tools include: Failure Mode Effects Analysis 
(FMEA), Failure Mode, Effects and Criticality Analysis 
(FMECA), Fault Tree Analysis (FTA), operational safety 
analysis and Hazard Analysis and Critical Control Points 
(HACCP), as well as the basic supporting risk management 
methods for flowcharts, control charts, etc. [1]. 
Using the species and impact analysis (FMEA) 
method, risk factors were identified during the 
pharmaceutical development phase of the drug “Fenspiride 
hydrochloride, coated tablets, 0.08 g”. Risk factors were 
ranked based on priority risk number (PRN) according to 
the Pareto diagram. The Pareto analysis showed that the 
most critical are the following risk factors: tablet size, bulk 
density of powdered tablet mass during tableting, bulk 
density of granulate after calibration [2]. 
Using the HACCP method, the analysis of 
dangerous factors that may affect the quality of the dosage 
form “Chondroitin sodium sulfate, injection solution 100 
mg / ml in ampoules of 2 ml”. For each potentially 
dangerous factor, the probability of its occurrence was 
estimated. Critical stages of the technological process and 
critical control points were identified; set critical limits for 
each checkpoint; a monitoring system for control points 
has been developed [3]. 
Using the method of cause and effect analysis, the 
potential factors that have the most significant impact on 
the quality of “Niavit, solution for injection”, in terms of 
mechanical inclusions, were identified. Critical quality 
parameters of the initial components and properties of the 
product have been identified, the most likely risks to the 
quality of the preparation have been identified, analysed 
and evaluated [4]. 
Application of general principles and approaches 
of the Guideline “Medicines. Quality Risk Management 
(ICH Q9)”at the stage of pharmaceutical development, 
using appropriate risk management tools both in general to 
the manufacture of medicines and to individual processes 
is an effective measure of quality assurance for the 
developed medicinal product. 
A necessary element of pharmaceutical 
development under the principle of “Quality by design” 
(QbD) is a general risk assessment, which is expressed in 
the relationship of the characteristics of materials and 
process parameters with critical indicators of the quality of 
the drug [5]. 
Despite the general approach, plans for 
pharmaceutical development experiments, quality targets, 
critical quality indicators and critical process parameters 
will be dramatically different for drugs in different dosage 
forms, as well as for different drugs in the same dosage 
form that should be considered when planning each 
development and each technology transfer [6, 7]. 
The technology of the combined dental gel was 
developed taking into account its properties as a dispersed 
system, as well as the properties of the active and auxiliary 
substances that are part of it. In order to manage quality 
risks effectively, it is necessary to have data about the 
sustainability of the process. Critical process parameters 
that need to be managed or monitored to ensure the 
required quality of the drug should be identified and 
specified. 
The aim of the work was to identify, through one 
of the risk management tools, the HACCP method, 
potential factors that may affect the quality of a combined 
dental gel containing metronidazole benzoate, miramistin, 
hyaluronic acid. It was necessary to analyse the developed 
technology and production scheme, identify critical control 
points, criteria for their acceptability, develop corrective 
and preventive actions when the parameter goes beyond the 
limits, and evaluate the possible risk to quality. 
 
Materials and methods  
The subject of the study was the technology and 
technological scheme of the production of a combined gel 
for the treatment of infectious diseases of the mucous 
membrane of the mouth and gums. Hazard Analysis and 
Critical Control Points (HACCP) were used to evaluate and 
manage risks in the manufacture of the new drug. The 
HACCP method is a structured method for identifying 
hazards and establishing control measures at all stages of 
the process to prevent hazards and maintain product quality 
and safety. 
The HACCP tool, the “Decision tree”, was used 
to establish critical control points. The standard “Decision 
tree” consists of questions that make it possible to decide 
whether a production process control point is critical to 
managing a potential hazard. 
 
Results and discussion 
An expert group of experts conducted an analysis 
and evaluation of the danger of individual stages of the 
technological process and determination of the criticality 
of the controlled parameters. The group consisted of 
qualified specialists from the pharmaceutical development 
department, thefactoryworkshop for the production of soft 
medicines, the quality control department. Expert team 
members are theoretically and practically aware of the use 
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Fig. 1 . Flow chart of production of combined dental gel 
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Analysis of the technological scheme of 
production of combined dental gel, which is shown in 
figure 1, showed that the production process consists of the 
general stages that are present in any technological process 
of drug production. 
Sanitary preparation for production, marking and 
packaging of finished products are stages that are standard and not 
directly related to technology. 
Almost all stages of the dental gel manufacturing process 
are critical and marked in grey. Using the tool “Decision tree”, we 
identified the critical control points of the technological process of 
gel production, and set the eligibility criteria. The results of the 
studies are shown in table 1. 
 
 
Table 1. Critical stages, critical control points (process parameters) and acceptability criteria for dental gel 
manufacturing technology 
 
Critical stages Critical parameters Acceptability criteria 
Stage 1  
Preparation and weighing 
of components 
accuracy of weighing of components Ensures the correct selection of scales 
with the required measurement limits 
and accuracy of weighing 
mass of components According to the production recipe and 
production protocol of the series 
input control of raw materials Availability of analysis protocols and 
manufacturing authorization 
Stage 2  
Preparation of solution for 
neutralization 
mixing time 20÷25 min 
the rotational speed of the mixer 300÷500 rpm 
completeness of dissolution the solution should be transparent 
Stage 3 
Preparation of miramistin 
solution 
mixing time 15÷25 min 
the rotational speed of the mixer 300÷500 rpm 
completeness of dissolution the solution should be transparent 
Stage 4 
Preparation of a solution 
of sodium salt of 
hyaluronic acid 
mixing time 20÷30 min 
the rotational speed of the mixer 300÷500 rpm 
completeness of dissolution the solution should be transparent 
Stage 5 
Preparation of a 
suspension of 
metronidazole benzoate 
homogenization time 5÷10 min 
the speed of rotation of the homogenizer 3000÷4000 rpm 
completeness of dispersion the absence of non-dispersed 
particles 
Stage 6 
Preparation of gel base 
mixing time 30÷35 min 
the rotational speed of the mixer 50÷60 rpm 
completeness of dispersion the absence of non-dispersed 
particles 
mixing time 50÷60 min 
the rotational speed of the mixer 20÷30 rpm 
the uniformity of the gel the gel should be homogeneous 
Stage 7 
Preparation of gel 7.1 
Adding a suspension of 
metronidazole benzoate 
mixing time 20÷30 min 
the rotational speed of the mixer 50÷60 rpm 
distribution uniformity the gel should be homogeneous 
7.2 Adding a solution of 
hyaluronic acid sodium 
salt 
mixing time 20÷30 min 
the rotational speed of the mixer 50÷60 rpm 
distribution uniformity the gel should be homogeneous 
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Critical stages Critical parameters Acceptability criteria 
7.3 Adding a solution of 
miramistin 
 
mixing time 20÷30 min 
the rotational speed of the mixer 50÷60  rpm 
distribution uniformity the gel should be homogeneous 
7.4 Homogenization 
 
homogenization time 5÷10 min 
the speed of rotation of the homogenizer 3000÷4000 rpm 
the homogeneity of the suspension the gel should be homogeneous 
the quality of the gel  as required by the specification 
Stage 8 
Gel dosage 
setting the dosage value 10.4 each 
the mass of the contents of the tube not less than 10 g 
control of the appearance of the tubes no mechanical damage, dirt on the 
tubes 
tightness control of tubes must be hermetically sealed 
quality control of the gel in the tubes as required by the specification 
control of storage conditions do not store above 25 ° C 
 
Risk factors were evaluated on the basis of two 
indicators: the likelihood of a hazard factor and the degree 
of risk created by that factor. The likelihood of a risk factor 
was as follows: 
- unlikely - 1 time / month to 1 time / year; 
- quitelikely - 1 time / week to 1 time / month; 
- probably - 1 time / day up to 1 time / week; 
- very likely - more than 1 time / day. 
The degree of risk was assessed on a ten-point 
scale, where 0 is no risk, 1-4 is low risk, 5-6 is medium 
risk, 7-9 is high risk, 10 is very high risk. 
During the processing of the gel technology, 
certain critical control points were monitored with the aim 
of developing preventive and corrective actions in case of 
their fall outside the eligibility criteria. The risk factors and 
the steps taken to address them are listed in table 2. 
 
Table 2. Risk factors and preventive actions in combined dental gel production 
Name of critical 
operation 
Risk factors The likelihood 
of a risk factor 




Input control of 
raw materials 
Microbiological unlikely Microbiological 
contamination of 
raw materials 
Control of storage conditions, 
control of conformity of 
packing to requirements of 
specification, control of terms 
of storage of raw materials 
2 








Physical unlikely The mismatch of 




Control of weighing, check of 
terms of metrological scales, 










Control of the solution 
preparation mode 
6 
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The use of the micronized 
substance metronidazole 
benzoate, 
control of homogenization 
mode 
7 
Chemical unlikely Excess content 
of admissible 
impurities 
Temperature control 5 
Preparation of 
gel base 
Physical quite likely  The 
heterogeneity of 
the gel base 
Control of the time of swelling 









substances in the 
gel 
Mixing mode control 7 
 
As can be seen from table 2, in the process of gel 
production, risk (physical factor) at the stages of 
metronidazole suspension preparation, preparation of gel 
base and gel directly is “Quite likely”. “Unlikely” 
occurrence of a dangerous factor at such stages as the 
weighing of active and auxiliary substances, the 
preparation of solutions and during the input control of raw 
materials. The risk level of each factor, ranging from 2 to 7 
points, was determined and corrective and preventive 
actions were developed for all critical control points to 
prevent risks to the quality of the medicinal product. 
 
Conclusions 
On the basis of the data obtained in the 
development of dental gel technology and using scientific 
knowledge and methodology of risk assessment by the 
method of HACCP, an analysis of technological scheme of 
its production was carried out. Process risks have been 
identified, critical control points have been identified and 
their allowed limits. For each control parameter, the 
probability of occurrence and the degree of risk were 
determined, and measures were proposed to prevent or 
eliminate the effects of the risk. The results obtained will 
then be used for the overall risk assessment of the quality 
of the new drug and validation of the technological process 
of its production. 
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unlikely, quitelikely, probably, very likely. The degree of 
risk was assessed on a ten-point scale. During the 
processing of the gel technology, certain critical control 
points were monitored with the aim of developing 
preventive and corrective actions in case of their fall 
outside the eligibility criteria. in the process of gel 
production, risk (physical factor) at the stages of 
metronidazole suspension preparation, preparation of gel 
base and gel directly is “Quite likely”. “Unlikely” 
occurrence of a dangerous factor at such stages as the 
weighing of active and auxiliary substances, the 
preparation of solutions and during the input control of 
raw materials. The risk level of each factor, ranging from 
2 to 7 points, was determined and corrective and 
preventive actions were developed for all critical control 
points to prevent risks to the quality of the medicinal 
product. Conclusions. Based on the data obtained in the 
development of dental gel technology and using scientific 
knowledge and methodology of risk assessment by the 
method of HACCP, an analysis of technological scheme 
of its production was carried out. Process risks have been 
identified, critical control points have been identified and 
their allowed limits. For each control parameter, the 
probability of occurrence and the degree of risk were 
determined, and measures were proposed to prevent or 
eliminate the effects of the risk. 
Keywords: quality risks, HACCP method, 
technological process, control critical points, dental gel. 
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